AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02197494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 320mg tablets
Study NCT00042510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treatment group
Study NCT03635801 — intervention group
Intervention type: DEVICE
Intervention: MyoVista 12 lead Electrocardiogram (ECG)
Description: MyoVista 12 Lead Electrocardiogram (ECG)
Study NCT04078373 — intervention group
Intervention type: BEHAVIORAL
Intervention: Immediate urination
Description: Patients with decreased cognitive ability will be taught to immediately go to the toilet upon feeling the urge to urinate and to be independent in urinating.
Study NCT04078373 — intervention group
Intervention type: BEHAVIORAL
Intervention: Bladder diary
Description: Patients with normal cognitive abilities will be instructed to go to the toilet every 2-3 hours regardless of the urge to urinate
Study NCT00606892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline (1 mg per day) given for 4 days prior to laboratory session
Study NCT00606892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar Pill
Study NCT00606892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Nic
Description: IV Nicotine given during the laboratory session following 4 days of exposure to the study medication (varenicline or placebo). This nicotine was given during each laboratory session which followed the 4 days of exposure to either placebo then varenicline or varenicline then placebo.
Study NCT00234832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine hydrochloride
Description: One 10 mg tablet QD plus country-specific standard care for weight management. (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
Study NCT00234832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet QD plus country-specific standard care for weight management (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
Study NCT00234832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine hydrochloride
Description: 10 mg tablet QD during the 6-week Lead-in Period plus country-specific standard care for weight management
Study NCT03672188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection
Study NCT01258140 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Computed tomography pulmonary angiography
Description: CT pulmonary angiography using iodinated contrast agent
Study NCT00793455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational outreach
Description: Participants will get a letter from their physician that explains that their records show the test has not been completed. The letter will be mailed along with an educational brochure and a DVD about colorectal cancer and colorectal cancer screening.
Study NCT03902665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Up-front allogeneic hematopoietic stem cell transplantation (HSCT)
Description: Patients classified as fit/unfit are included in the HSCT program. There are two early approaches allowed. A) Patients will be left untreated until HSCT B) Patients will receive 1 short course of chemotherapy before HSCT (Ara-C and anthracycline).~Selection of strategy A or B, will be patient based on disease characteristics and dynamics or presence of high tumor load.~Conditioning for haplo-HSCT should be started as soon as possible, within day 45 after initial diagnosis. This is to avoid delayed transplantation. Two dosing levels of the Thiotepa-Busulfan-Fludarabine (TBF) based protocol are allowed based on the clinical condition of the patient: fit patients below 70 will receive the TBF with 2 days of Busulfan, whereas patients with poorer clinical condition or above the age of 70 will receive a dose-reduced TBF, in which Busulfan may be reduced to 1 day only.
Study NCT01914289 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Study NCT02924831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Stimulating acupoints by using stainless steel needles with manual manipulation.
Study NCT02924831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moxibustion
Description: Stimulating acupoints by using burned moxa
Study NCT02924831 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Stimulating acupoints by using stainless steel needles without manual manipulation.
Study NCT01899339 — intervention group
Intervention type: OTHER
Intervention: submassive PA treatment with Ekosonic endo device
Description: Ultra Sound energy along with tPA to treat submassive pulmonary embolism
Study NCT02478229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) and Ledipasvir (LDV)
Study NCT04047992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indego™ Exoskeleton
Description: The Indego® is a powered exoskeleton that can be used as a mode of therapy in an institutional setting. Proper walking in this device requires the user to manipulate their center of gravity and balance by postural trunk excursions in order for the legs to take steps.
Study NCT02260661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8835
Description: AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
Study NCT02260661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8835
Description: AZD 8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
Study NCT02260661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8835 in combination with fulvestrant
Description: AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy.
Study NCT01914289 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT03108664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL1001 ophthalmic solution
Description: 1 drop in the affected eye
Study NCT02260661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8835 in combination with fulvestrant
Description: AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy
Study NCT03857477 — intervention group
Intervention type: GENETIC
Intervention: Genetic SNP profiling
Description: Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.
Study NCT03108664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle opthalmic solution
Description: 1 drop in the affected eye
Study NCT03672188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% NaCl) given by subcutaneous injection
Study NCT00782262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: KicStart™
Description: KicStart™ is a nutritionally complete, but lower energy formulated liquid meal. Two sachets of KicStart™ (one for breakfast and one for lunch) provides 450 cal of energy per day, 0.8 grams per kilogram ideal body weight of high quality protein, and the recommended daily allowances (RDI) of minerals, vitamins, trace elements, omega 3 and 6 essential fatty acids. The Kicstart is supplemented with some salads, carbohydrate free vegetables and a small piece of meat fish or chicken each day in order to achieve a total energy intake of approximately 850 kcals/day.
Study NCT03857477 — intervention group
Intervention type: OTHER
Intervention: Prostate cancer screening
Description: Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.
Study NCT03857477 — intervention group
Intervention type: PROCEDURE
Intervention: MRI Scan
Description: MRI scan will be offered to men identified within the top 10% genetic risk score profile.
Study NCT03857477 — intervention group
Intervention type: PROCEDURE
Intervention: Prostate biopsy
Description: Transperineal prostate biopsy under local anaesthetic will be offered to men identified within the top 10% genetic risk score profile.
Study NCT03707574 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue
Study NCT02315911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ATE
Description: surgical removal of adenoids and tonsils
Study NCT02315911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: APP
Description: surgical removal of adenoids and tonsils and suturing of palatal pillars
Study NCT02035111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianshu capsule
Study NCT02035111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Study NCT00354913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: Hydroxyurea is administered orally twice a day. The dose will be set at 500 mg twice a day for all patients. If vomiting occurs not additional trial medication should be taken that day in an effort to replace the material that has been vomited. It is recommended that patients take their prescribed hydroxyurea at the same time that they take their prescribed imatinib mesylate, however, a 30-60 minute interval between agents is acceptable, if required for practical or other compliance issues.
Study NCT00354913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Imatinib administered orally on daily, continuous basis. Imatinib doses of 400mg/600mg administered once daily, whereas daily doses of 800mg/greater administered as equally divided dose taken twice day.~Dose for Imatinib:~Patients receiving p450-inducing antiepileptic drugs:500mg twice day Patients not receiving p450-inducing antiepileptic drugs:400mg/day.~If patients who were not on Cytochrome P450, family 3, subfamily A (CYP3A) enzyme-reducing anti-epileptic drug (EIAED) when originally enrolled must initiate CYP3A enzyme-inducing anti-epileptic drug while on study, study regimen will remain same for minimum of 2 wks before pt transitions to dosing as specified for patients on anti-epileptic drug. If patients originally enrolled must discontinue all EIAEDs while on study, in interest of patient safety, dosing of study regimen will transition to that of patients not on anti-epileptics immediately.
Study NCT02392117 — intervention group
Intervention type: DRUG
Intervention: insulin degludec
Description: Tresiba® will be prescribed by the physician under normal clinical practice conditions and will be obtained/ purchased from the chemist based on physician prescription. No treatment given.
Study NCT01540474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group 1: 10 ug FMP012 with 2 ug GLA-SE
Description: Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
Study NCT01540474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group 2: 10 ug FMP012 with 5 ug GLA-SE
Description: E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
Study NCT01540474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE
Description: E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
Study NCT01540474 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Controlled group-Challenged Only: no vaccination
Description: The control group participated in the primary malaria sporozoite challenge.E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
Study NCT03302494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coherex WaveCrest® Left Atrial Appendage Occlusion System
Description: Percutaneous left atrial appendage closure
Study NCT03302494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Watchman® LAA Closure Device
Description: Percutaeous left atrial appendage closure
Study NCT00547716 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Description: Omega-3 Fatty Acids - 4 grams per day
Study NCT00547716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Study NCT03512041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RLIC - 5 cycles
Description: RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
Study NCT03512041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RLIC - 4 Cycles
Description: RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
Study NCT03512041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RLIC - 3 Cycles
Description: RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
Study NCT03512041 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham conditioning
Description: Sham conditioning is achieved as listed in the arm/group descriptions. Sham conditioning is performed on visits 1-7, which occur on consecutive weekdays.
Study NCT03512041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training
Description: All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
Study NCT03512041 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Balance training
Description: All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
Study NCT03512041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm training
Description: All participants undergo training on a cup stacking task, learning to assemble and disassemble cup configurations as fast as they can. Participants perform the cup stacking task 5 trials per day at visits 3-7.
Study NCT03512041 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Arm training
Description: All participants undergo training on a cup stacking task, learning to assemble and disassemble cup configurations as fast as they can. Participants perform the cup stacking task 5 trials per day at visits 3-7.
Study NCT03512041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequence production training
Description: All participants undergo training on a discrete sequence production task. Participants learn to associate specific color and shape symbols with sequences of key presses on a keyboard. Participants perform the sequence production task for 10-15 minutes per day at visits 3-7.
Study NCT03512041 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sequence production training
Description: All participants undergo training on a discrete sequence production task. Participants learn to associate specific color and shape symbols with sequences of key presses on a keyboard. Participants perform the sequence production task for 10-15 minutes per day at visits 3-7.
Study NCT01818453 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized self-help program for depression
Description: For 8 weeks, participants will engage in a computerized self-help program for depression, called deprexis. This program consists of 10 content modules representing different psychotherapeutic approaches broadly consistent with a cognitive-behavioral perspective. Modules are organized as simulated dialogues in which the program explains and illustrates concepts and techniques, engages the user in exercises, and continuously asks users to respond by selecting from response options. Subsequent content is then tailored to the users' responses, resulting in a simulated conversational flow. Participants can access the self-help program as often as they would like and since it is self-guided, they will determine how often they access the material. Each module can be completed in 10 to 60 minutes, depending on the user's reading speed, interest, motivation, and individual path through the program.
Study NCT03472118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal High Flow Oxygen
Description: Nasal High Flow Oxygen during apnoea using Optiflow device of Fisher and Paykel
Study NCT01922102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5mg
Description: 0.5 mg ranibizumab (intravitreal injections)
Study NCT01922102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: 0.5 mg ranibizumab (intravitreal injections)
Study NCT01922102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin PDT
Description: Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application
Study NCT00638508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
Study NCT00638508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac and Ropivacaine
Description: Patients will receive Ketorolac at 5 mg/hr plus 0.5% Ropivacaine
Study NCT00983216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: A single dose of colchicine 0.6 mg administered alone at 7:30 a.m. on Day 1.
Study NCT00983216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: one 200 mg Ketoconazole tablet administered twice daily at 7:15 a.m. and 7:15 p.m. on Days 15-18 without regard to meals, then along with colchicine at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 200 mg administered at 7:15 p.m. on Day 19
Study NCT00983216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: A single dose of colchicine 0.6 mg administered along with ketoconazole at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours
Study NCT04238728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silverlon
Description: silver nylon dressing will be applied daily
Study NCT02550457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional elastic tape tensioned
Description: Application of Kinesio Taping with tension in the erector spine muscles.
Study NCT02550457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional elastic tape non-tensioned
Description: Application of Kinesio Taping without tension in the erector spine muscles.
Study NCT02550457 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rigid Tape
Description: Application of Micropore tape in the erector spine muscles.
Study NCT02703571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Combination treatment with LEE and TMT
Study NCT02703571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Combination treatment with LEE and TMT
Study NCT01072695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9256
Description: 75 mg BID x 28 days
Study NCT00974896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
Study NCT03781167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: Solution for continuous subcutaneous infusion (CSCI)
Study NCT02442427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palivizumab
Description: A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg). The study medication will be given by IV infusion over 30 minutes using a syringe infusion pump.
Study NCT02442427 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An equal volume of 0.9% normal saline
Study NCT02985541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUS (Mirena, BAY86-5028)
Description: Levonorgestrel (LNG) intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg levonorgestrel per day.
Study NCT00060320 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: black cohosh
Study NCT00060320 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: black cohosh
Study NCT00060320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT00060320 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00917904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapivirine
Description: dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks
Study NCT00917904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: dosage form: vaginal gel~frequency: once daily~duration: 6 weeks